Saniona clears obstacle ahead of new trial
The US health authorities have now received the all of the requested documentation for the capsule version of the biotech company's candidate Tesomet. Saniona's plans to begin a clinical trial with the drug before the end of year thus remain unchanged.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
After dialog with the US Food and Drug Administration (FDA), the biotech company Saniona is sticking to its plans to initiate a phase IIb trial of its drug Tesomet before the end of the year, it reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Saniona borrows USD 10m for clinical studies
For subscribers
FDA gives Saniona candidate priority status
For subscribers
